Skip to main content
Caplight Logo









Elucid

Elucid

Private
Boston, MassachusettsHealthcare & Life Scienceshttps://elucid.com

Last Round

Series D

Sep 2, 2026

Total Funding Raised

$170.75M

Momentum

Top 25%

of companies Caplight tracks

Company Overview

Elucid is a medical technology company that develops AI-powered imaging software to quantify and characterize atherosclerotic plaque for personalized cardiovascular disease treatment.

Sector

Healthcare & Life Sciences

Verticals

Medical Imaging, Medical AI, Medical Devices, Healthcare Analytics, Precision Medicine

Business Model

B2B

Customer Profile

Services & Consulting, Usage-Based SaaS

AI Layer

Application

Keywords

cardiovascular imagingAI medical imagingmedtechplaque characterizationFFR-CTfractional flow reservecardiovascular diagnosticsnon-invasive diagnosticsmedical AIcardiology softwareclinical decision supportAI radiologydigital healthusage-based billing

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Elucid Comparables

Compare Elucid with similar companies based on industry and business-model similarity.

Elucid comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Cleerly
91%
Artrya Ltd
83%
Circle Cardiovascular Imaging
83%

Elucid Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series DSep 2, 2026
Series CNov 9, 2023
Series BJun 22, 2022
Series AMay 10, 2021
GrantSep 1, 2015

Elucid Investors

Notable investors and investment history

Elucid investors
InvestorRounds
Bold BrainSeries B
IAG Capital PartnersSeries B, Series A, Series D
MedTex VenturesSeries B, Series C, Series A
NIH RADxGrant
BiovergeSeries B
Willamette Valley CapitalSeries A
Checkmate CapitalSeries A

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 2, 2026

    $55M round with IAG Capital Partners and Elevage Medical Technologies.

  • Apr 15, 2026

    Commercial availability of the Lesion Inspection Tool for plaque analysis.

Elucid Filings

Explore SEC and related filing metadata, where available.

Elucid filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Elucid's valuation, stock price, and market status.

Is Elucid a public or private company?

Elucid is a private company.

What is the current stock price of Elucid?

Elucid is a private company, so its shares have no public market price. Caplight tracks Elucid's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Elucid worth (valuation)?

Valuation information for Elucid is not publicly available.

Can I buy Elucid stock?

Elucid shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Elucid's last funding round?

Elucid's most recent funding round was Series D on September 2, 2026.

Who are the main investors in Elucid?

Key investors in Elucid include MedTex Ventures, Elevage Medical Technologies.

Will Elucid IPO soon?

No public IPO plans have been announced for Elucid.

How can I track Elucid secondary market activity?

Caplight tracks bids, offers, and trades in Elucid's shares on secondary markets.

Firmographic Details

HeadquartersBoston, Massachusetts
Employee Range105
Year Founded2009
Last FundingSep 2, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?